Lutetium Lu 177 dotatate Active Not Recruiting Phase 2 Trials for Neuroendocrine Tumors Treatment

IndicationsStatusPurposePhase
Active Not RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01237457177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms